Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics
(NQ:
CLDX
)
36.34
-0.42 (-1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
539,490
Open
37.22
Bid (Size)
35.23 (1)
Ask (Size)
41.72 (1)
Prev. Close
36.76
Today's Range
36.11 - 37.86
52wk Range
22.11 - 53.18
Shares Outstanding
65,910,548
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analyst Expectations For Celldex Therapeutics's Future
July 16, 2024
Via
Benzinga
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-10.07%
-10.07%
1 Month
+3.03%
+3.03%
3 Month
-6.46%
-6.46%
6 Month
-9.06%
-9.06%
1 Year
-2.83%
-2.83%
More News
Read More
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 04, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
June 03, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Celldex Therapeutics
May 07, 2024
Via
Benzinga
Celldex Therapeutics: Q4 Earnings Insights
February 26, 2024
Via
Benzinga
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
December 20, 2023
Via
Benzinga
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
May 15, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 06, 2024
Via
InvestorPlace
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 08, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
March 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
February 29, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 28, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Via
Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
February 26, 2024
Via
Investor's Business Daily
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Top Picks 2024: Celldex Therapeutics, Inc.
January 28, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.